B+
Bull case
30%
Probability
Target price
$185.00
Analysis reference price unavailable
Analysis 2026-04-17 · RankAlpha Sentiment Codex
PVLA
Palvella TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
PVLA now has positive Phase 3 SELVA data, an intended 2H 2026 NDA, and materially improved liquidity after the February 2026 financing, which together support a credible path to a first commercial product in a disease with no FDA-approved therapies [#PR-2026-02-24][#PR-2026-03-31].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +3.6.
What can break
Commercial launch execution risk if approved in a rare-disease market.
Momentum
61
Value
41
Sentiment
43
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $125.00 · Bull $185.00 · Bear $70.00Analysis 2026-04-17; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $229.20
Why
Momentum61 · Δ7d +15.4
Value41 · Δ7d 0.0
Sentiment43 · Δ7d +3.6
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +3.6.
Contradictions & invalidation
- • Commercial launch execution risk if approved in a rare-disease market.
- • Further capital needs or dilution if timelines extend beyond current plans.
- • The story is still heavily concentrated in QTORIN rapamycin, forward visibility beyond the lead program is limited, and the deterministic packet is only middling on evidence quality with low catalyst density; any filing, CMC, or review delay could compress the multiple quickly.
Catalyst clock
2026-06-30
Phase 2 angiokeratoma study initiation expected in Q2 2026
Lead driver: Sentiment · See AI snapshot
Momentum
61
9% active weight
Current posture
7d trendImproving
Δ7d
+15.4
Δ21d
-23.5
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
43
62% active weight
Current posture
7d trendImproving
Δ7d
+3.6
Δ21d
+0.8
Why this grade
Composite grade D. Momentum 61.5 / Value 41.2 / Sentiment 43.3
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-17. Scenario method
Most likely
B
Base case
40%
Probability
Target price
$125.00
Analysis reference price unavailable
Analysis 2026-04-17 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$70.00
Analysis reference price unavailable
Analysis 2026-04-17 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$2.21B
Beta
-0.15
Shares Out
14.41M
P/E (TTM) · Derived
-41.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-53.75
Rev YoY
-100.0%
EPS YoY
+77.8%
Gross Margin
+94.5%
Op Margin
-26594.3%
Net Debt
-$39.59M
Current Ratio
21.18
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data